About Avila Therapeutics
Avila Therapeutics is a company based in Waltham (United States) founded in 2006 was acquired by Celgene in January 2012.. Avila Therapeutics has raised $57.5 million across 4 funding rounds from investors including Novartis, Celgene and Atlas Venture. Avila Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Waltham, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Avila Therapeutics, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Avila Therapeutics
Avila Therapeutics has successfully raised a total of $57.5M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $22.5 million completed in June 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $22.5M
- First Round First Round
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2010 | Amount | Series B - Avila Therapeutics | Valuation |
investors |
|
| Jul, 2009 | Amount | Series B - Avila Therapeutics | Valuation | Novartis | |
| May, 2009 | Amount | Series A - Avila Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Avila Therapeutics
Avila Therapeutics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Novartis, Celgene and Atlas Venture. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early stage venture capital firm investing in US
|
Founded Year | Domain | Location | |
|
VC & PE firm
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in life science and biotechnology sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Avila Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Avila Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Avila Therapeutics Comparisons
Competitors of Avila Therapeutics
Avila Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Avila Therapeutics
Frequently Asked Questions about Avila Therapeutics
When was Avila Therapeutics founded?
Avila Therapeutics was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Where is Avila Therapeutics located?
Avila Therapeutics is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Is Avila Therapeutics a funded company?
Avila Therapeutics is a funded company, having raised a total of $57.5M across 4 funding rounds to date. The company's 1st funding round was a Series A of $5M, raised on Aug 20, 2007.
What does Avila Therapeutics do?
Avila Therapeutics was founded in 2006 and headquartered in Waltham, United States, within the biotechnology sector. Targeted covalent inhibitors, particularly tyrosine kinase inhibitors, were designed and developed using the proprietary Avilomics platform. The pipeline addressed cancer, viral infections, and autoimmune diseases, with AVL-292 advancing to Phase 1 clinical trials for cancer and autoimmune indications. The company was acquired by Celgene in March 2012.
Who are the top competitors of Avila Therapeutics?
Avila Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Who are Avila Therapeutics's investors?
Avila Therapeutics has 7 investors. Key investors include Novartis, Celgene, Atlas Venture, Abingworth, and Advent Venture Partners.